Curadev Pharma

Noida, India Founded: 2010 • Age: 16 yrs
Small molecule immunotherapy drugs for cancer and inflammation are developed.
Annual revenue $1.7M Latest available
Total funding $881,100 2 rounds
Employees 46 Tracked headcount
Investors 4 Known backers
Products 3 Services tracked
Competitors 8 Brand Intelligence

About Curadev Pharma

Curadev Pharma is a company based in Noida (India) founded in 2010 by Arjun Surya and Manish Tandon. Curadev Pharma has raised $881.1 thousand across 2 funding rounds from investors including Department of Biotechnology, Vasantha Surya and Arjun Surya. The company has 46 employees as of April 03, 2024. Curadev Pharma offers products and services including STING Agonist CRD3874-SI, Vaccine Adjuvants, and Acetate Metabolism Modulators. Curadev Pharma operates in a competitive market with competitors including Syndax, Annexon, Auron Therapeutics, Clovis Oncology and C4X Discovery, among others.

  • Headquarter Noida, India
  • Employees 46 as on 03 Apr, 2024
  • Founders Arjun Surya, Manish Tandon
  • Stage Minicorn
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Curadev Pharma Private Limited
  • Date of Incorporation 07 Jan, 2010
  • Jurisdiction New Delhi, Delhi, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $1.67 M (USD)
    -60.66
    as on Mar 31, 2023
  • Net Profit
    -$4.35 M (USD)
    -186.97
    as on Mar 31, 2023
  • EBITDA
    -$5.03 M (USD)
    -50.33
    as on Mar 31, 2023
  • Total Equity Funding
    $881.1 K (USD)

    in 2 rounds

  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    46

    as on Apr 03, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Curadev Pharma

Curadev Pharma offers a comprehensive portfolio of products and services, including STING Agonist CRD3874-SI, Vaccine Adjuvants, and Acetate Metabolism Modulators.

Product name locked
Category locked
Primary

Therapeutic for advanced cancer treatment in clinical trials

Product name locked
Category locked
Locked

Compounds enhancing immune response in vaccines

Product name locked
Category locked
Locked

Agents targeting metabolic pathways for disease treatment

Funding Insights of Curadev Pharma

Curadev Pharma has successfully raised a total of $881.1K across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Curadev Pharma

Curadev Pharma has secured backing from 4 investors, including institutional and angel investors. Prominent investors backing the company include Department of Biotechnology, Vasantha Surya and Arjun Surya.

All
Institutional
Angel
Investor Description Founded Year Domain Location
Biotechnology research, guidelines, and funding by the Government of India.
Locked Locked Locked

Vasantha Surya

-
Locked Locked Locked

Arjun Surya

-
Locked Locked Locked
Premium access

Investor details for Curadev Pharma

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Curadev Pharma

Investments
Premium access

Investment portfolio details for Curadev Pharma

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Curadev Pharma

Premium access

Detailed financials for Curadev Pharma

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Curadev Pharma Comparisons

Curadev Pharma Primary company
Description
Small molecule immunotherapy drugs for cancer and inflammati...
Location
Noida, India
Founded Year
2010
Annual Revenue
$1.67 M (USD)
Net Profit
-$4.35 M (USD)
EBITDA
-$5.03 M (USD)
Employees
46
As of 2024
Premium access

Peer comparison for Curadev Pharma

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Curadev Pharma

Curadev Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Syndax, Annexon, Auron Therapeutics, Clovis Oncology and C4X Discovery, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Targeted therapies for cancer treatment are developed.
Locked Locked Locked
Developer of antibodies to treat complement-mediated neurodegenerative diseases
Locked Locked Locked
Developer of cancer therapeutics for the treatment of blood cancer
Locked Locked Locked
Develops innovative immunotherapy drugs for cancer treatment.
Locked Locked Locked
Developer of optimized drug discovery and design services
Locked Locked Locked
Anti-cancer immunotherapies are developed targeting tumor micro-environment.
Premium access

Detailed competitors of Curadev Pharma

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Curadev Pharma

Premium access

Complete news archive for Curadev Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Curadev Pharma

Curadev Pharma was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Curadev Pharma is headquartered in Noida, India. It is registered at Noida, Uttar Pradesh, India.

Curadev Pharma is a funded company, having raised a total of $881.1K across 2 funding rounds to date.

As of Apr 03, 2024, the latest employee count at Curadev Pharma is 46.

Annual revenue of Curadev Pharma is $1.67M as on Mar 31, 2023.

Curadev Pharma was founded in 2010 in Noida, India, as a drug discovery company focused on immunotherapy. RD services are provided to clients alongside internal programs targeting cancer and inflammation. Patents for dual IDOTDO inhibitors, which address immune suppression by tumors, were licensed to Roche. Coverage includes solid and liquid tumors, breast cancer, and inflammatory conditions, with an investigational new drug application filed.

Curadev Pharma's top competitors include Syndax, iTeos Therapeutics and Annexon.

Curadev Pharma offers STING Agonist CRD3874-SI, Vaccine Adjuvants, and Acetate Metabolism Modulators.

Curadev Pharma has 4 investors. Key investors include Department of Biotechnology, Vasantha Surya, Arjun Surya, and Vasantha Surya.

The valuation of Curadev Pharma is $8.77M as of Mar 2011.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available